Charts Compass Therapeutics, Inc.

Equities

Delayed Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
1.47 ^USD	-1.67%		-8.12%	-5.77%

May. 23	Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024	CI
May. 13	Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

ProRealTime Chart